Stock report · Delisted · Nasdaq
Avidity Biosciences, Inc (RNAM)
71.34USD Delisted Final close · Feb 25, 2026
RNAM no longer trades. Avidity Biosciences was acquired by Novartis (NVS) in February 2026.
All prices on this page are historical. The last trade was on February 25, 2026, at $71.34.
RNAM stock price history
Final trading statistics
- Final close
- $71.34
- Final trading day
- Feb 25, 2026
- Market cap at delisting
- $11.02B
- Shares outstanding
- 154.48M
- Final 52-week range
- $21.51 – $73.06
- Avg. volume (final 3 mo.)
- 2,103,574
- All-time high
- $72.93 · Feb 2026
- All-time low
- $4.87 · Oct 2023
- Return since IPO
- +150.3%
- Beta
- 0.93
- Book value / share
- $11.17
- Price / book
- 6.39
About Avidity Biosciences, Inc
Avidity Biosciences, Inc. was a biopharmaceutical company delivering RNA therapies known as antibody oligonucleotide conjugates (AOCs). Its AOC platform paired the targeting of monoclonal antibodies with the precision of RNA drugs to address root causes of diseases not previously treatable this way.
Three programs were in clinical development: Delpacibart zotadirsen, in the Phase 2 EXPLORE44 open-label extension for Duchenne muscular dystrophy; Delpacibart etedesiran, in Phase 3 for myotonic dystrophy type 1; and Delpacibart braxlosiran, in Phase 1/2 for facioscapulohumeral muscular dystrophy. In cardiology, AOC 1086 targeted phospholamban cardiomyopathy and AOC 1072 targeted PRKAG2 syndrome (protein kinase AMP-activated non-catalytic subunit gamma 2).
Incorporated in 2012 and based in San Diego, California, it became a subsidiary of Novartis AG as of February 27, 2026. Novartis (NVS) acquired the company in February 2026, paying $72.00 in cash per share plus shares of a spun-off company (SpinCo). The stock last traded on February 25, 2026 at $71.34.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA
- Employees
- 511
- IPO date
- June 28, 2013
- Delisted
- February 25, 2026
Avidity Biosciences financials before the delisting
The last 5 fiscal years Avidity Biosciences reported as a public company, fiscal year ending December.
RNAM revenue and net income
RNAM earnings per share
RNAM annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $18.75M | −$684.6M | −$4.97 |
| FY2024 | $10.90M | −$322.3M | — |
| FY2023 | $9.56M | −$212.2M | — |
| FY2022 | $9.22M | −$174.0M | — |
| FY2021 | $9.33M | −$118.0M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Avidity Biosciences stock FAQ
What happened to Avidity Biosciences stock?
Avidity Biosciences was acquired by Novartis (NVS) in February 2026. The final close was $71.34 on February 25, 2026.
What did Avidity Biosciences shareholders receive?
Each RNAM share was converted into $72.00 in cash, plus shares of a spun-off company (SpinCo). The deal was valued at about $12 billion.
Can I still buy RNAM stock?
No. RNAM is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on February 25, 2026.
What was the last price of RNAM?
RNAM last closed at $71.34 on February 25, 2026, which valued the company at about $11.02B.
How did Avidity Biosciences do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Avidity Biosciences reported revenue of $18.75M and net income of −$684.6M.
When did Avidity Biosciences go public?
Avidity Biosciences shares started trading on June 28, 2013.
RNAM no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.